GSE208192
Liver in humanized-liver mice: Control vs ortho-toluidine treatment
The gene expression profiling between Control and ortho-toluidine exposure for 4 weeks in liver of NOG-TKm30 female mice transplanted with commercially available human hepatocytes. Overall design: Female 6- or 7-week-old NOG mice expressing HSVtk mutant clone 30 cDNA under the control of mouse transthyretin gene enhancer/promoter (NOG-TKm30 mice) were transplanted with commercially available human hepatocytes. After 9 or 8 weeks (16-week-old), mice were treated with 0 or 0.6% ortho-toluidine (OTD) for 1 week and 0 or 0.3% OTD for 3 weeks (totally 4 weeks treatment). After treatment, mice were sacrificed, and removed livers. Control and OTD treatment: 2 control female mice, 3 OTD-treated female mice, respectively. Mixed 2 or 3 samples from each group for each RNA-seq.